VKTX - Viking Therapeutics, Inc.
| Previous Close | 10.54 |
| Open | 10.46 |
| Bid | 10.49 x 1000 |
| Ask | 10.72 x 900 |
| Day's Range | 10.39 - 10.71 |
| 52 Week Range | 0.97 - 13.43 |
| Volume | 947,443 |
| Avg. Volume | 3,856,823 |
| Market Cap | 633.874M |
| Beta | 2.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.64 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.33 |
- Motley Fool•4 hours ago
Is Viking Therapeutics, Inc. a Buy?
No gnashing of teeth needed to make a call on this clinical-stage biotech.
- Motley Fool•4 days ago
3 Growth Stocks for in-the-Know Investors
Looking for a few good stocks that are flying under the radar?
- Zacks Small Cap Research•6 days ago
VKTX: Data from P2 Trial of VK2809 in 4Q18…
This was a multicenter, randomized, double blind, placebo controlled trial that enrolled a total of 108 subjects (83 women and 25 men) age ≥ 65 years of age who had suffered a hip fracture within the past three to seven weeks. Subjects were administered placebo or 0.5 mg, 1.0 mg, or 2.0 mg of VK5211 once-daily for 12 weeks (NCT02578095). The primary outcome of the trial was the change in lean body mass, less head, after 12 weeks of treatment.
- PR Newswire•10 days ago
Viking Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today - Enrollment complete for VK2809 Phase 2 fatty liver and hypercholesterolemia study, results expected 2H18 - Final results from Phase 2 VK5211 study for ...
- ACCESSWIRE•10 days ago
Viking Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Viking Therapeutics, Inc. (NASDAQ: VKTX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 4:30 PM Eastern ...
- PR Newswire•17 days ago
Viking Therapeutics to Report Financial Results for Second Quarter 2018 on August 9, 2018
Conference Call Scheduled for Thursday, August 9 at 4:30 p.m. Eastern Time SAN DIEGO , Aug. 2, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
- Bloomberg•20 days ago
Analyst-Turned-CEO Says His Biotech Stock Is Cheap, Even After a 900% Rally
Brian Lian used to cover biotechnology firms at SunTrust, but the former sell-side analyst has been running Viking for the past six years. Adds share move and Raymond James commentary in final paragraph.
- ACCESSWIRE•25 days ago
Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks
Stock Research Monitor: TPIV, VCEL, and VRTX LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on VKTX sign up now at www.wallstequities.com/registration . On Tuesday, July 24, ...
- Motley Fool•29 days ago
Should Biotech Investors Fear Dilution?
Biotechs are infamous for tapping the public markets for capital on a regular basis. Here is a look at how this standard practice can both damage and create value for shareholders.
- PR Newswire•last month
Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting
Presentation to Highlight Data for Novel, Orally Available SARM in Patients Recovering from Hip Fracture Surgery SAN DIEGO, Calif. , July 17, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. (" Viking ...
- Motley Fool•last month
3 Biotech Stocks With Big News Coming in NASH
The next big market for biopharma could be nonalcoholic steatohepatitis, so upcoming data from these companies could be market-moving.
Motley Fool•last month3 Top Biotech Stocks to Buy Right Now
This could be a good time to add a profit-friendly play, a clinical-stage upstart, and a make-or-break biotech to your portfolio.
- Motley Fool•last month
3 Top Biotech Stocks to Buy for the 2nd Half of 2018
Consider putting these large-cap, mid-cap, and small-cap biotech stocks on your buy list.
- Motley Fool•2 months ago
Viking Therapeutics, Buy the Dip?
Viking's shares finally pulled back last week. Should investors take advantage of this dip?
- Motley Fool•2 months ago
This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It
This NASH drug developer has a decent chance at beating all of its peers to market.
- Motley Fool•2 months ago
3 Small-Cap Biotech Stocks to Keep on Your Radar
Small market caps. Big opportunities.
- Motley Fool•2 months ago
Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
These two small biotechs with promising NASH drugs could attract several big suitors.
- Motley Fool•2 months ago
3 Growth Stocks at Deep-Value Prices
Attractively priced stocks with plenty of runway for growth give the best chance for outsized, long-term returns.
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within NovoCure, Canada Goose, Telephone and Data, FMC, MobileIron, and Viking Therapeutics — Discovering Underlying Factors of Influence
NEW YORK, June 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NovoCure ...
Market Realist•2 months agoWhy Viking Therapeutics Stock Rose on June 13
On June 13, Viking Therapeutics (VKTX) stock rose ~9.1%, triggered by positive mid-stage trial results for peer Galmed Pharmaceuticals’ (GLMD) NASH (non-alcoholic steatohepatitis) drug, Aramchol. For more on the development, read Why Galmed Pharmaceuticals Stock Rose 151% on June 12. Galmed’s positive study results buoyed investors’ hopes of success for Viking Therapeutics’ NASH candidate, VK2809, which is in mid-stage trials and has a similar mechanism of action. On June 13, the SPDR S&P Biotech ETF (XBI) rose ~0.26%.
- Motley Fool•2 months ago
Are These Red-Hot NASH Stocks Still a Buy?
Investors are piling into NASH stocks right now, but which ones are the best long-term buys?
- Motley Fool•2 months ago
Here's Why Viking Therapeutics Rose as Much as 14.9% Today
The clinical-stage biopharma is on a tear in recent weeks.
- Zacks Small Cap Research•2 months ago
VKTX: Final Patient Enrolled in P2 Trial of VK2809; Raises Gross Proceeds of $77.6M in Public Offering
Gross proceeds to the company will be approximately $77.6 million. The company exited the first quarter of 2018 with approximately $77.5 million in cash and cash equivalents. Following this most recent financing, we estimate the company will exit the second quarter of 2018 with between $140-$150 million, which should be sufficient to fund operations well into 2020.
- PR Newswire•2 months ago
Viking Therapeutics Announces Closing of Public Offering of Common Stock
Viking currently intends to use the net proceeds from the offering for continued development of its VK2809, VK5211 and VK0214 programs and for general research and development, working capital and general corporate purposes. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
- Motley Fool•2 months ago
2 Cheap Growth Stocks to Buy Right Now
Crispr Therapeutics and Viking Therapeutics are both grossly undervalued relative to their long-term prospects right now.
